Recent Press Releases

Multimedia assets now available: ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

Multimedia assets associated with the below announcement are now available. Assets include: b-roll footage, corporate sound bites, product images and additional information.

Moody's: Indian pharmaceutical sector to see strong growth

Moody's: Indian pharmaceutical sector to see strong growth Singapore, August 25, 2014 -- Moody's Investors Service says that India's pharmaceutical market will continue to grow in the...

Iroko Pharmaceuticals Gains FDA Approval of ZORVOLEX® for Management of Osteoarthritis Pain

Iroko Pharmaceuticals Gains FDA Approval of ZORVOLEX® for Management of Osteoarthritis Pain New Indication in Chronic Pain Marks Company's Third FDA Approval in Less Than a Year PHILADELPHIA,...

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection LONDON, Aug. 22, 2014 /PRNewswire/ --...

Roche and InterMune Reach Definitive Merger Agreement

Roche and InterMune Reach Definitive Merger Agreement Roche to acquire InterMune for $74.00 per share InterMune's lead product pirfenidone for idiopathic pulmonary fibrosis to expand Roche's...

Roche and InterMune Reach Definitive Merger Agreement

-- Roche to acquire InterMune for $74.00 per share --

BASEL, Switzerland, Aug.

U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy

· Eliquis demonstrated noninferiority in the primary efficacy endpoint of recurrent symptomatic venous thromboembolism (VTE) or VTE-related death versus enoxaparin/warfarin in the...

Mylan Launches First Generic Klor-Con® Extended-Release Tablets

Mylan Launches First Generic Klor-Con® Extended-Release Tablets PITTSBURGH, Aug. 22, 2014 /PRNewswire/ -- Mylan Inc. (MYL) today announced that it has launched Potassium Chloride Extended-release...

Cubist Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review

Cubist Announces EMA Acceptance of Ceftolozane/Tazobactam Marketing Authorization Application for Review LEXINGTON, Mass., Aug 22, 2014 (BUSINESS WIRE) -- Cubist Pharmaceuticals, Inc. CBST, +0.19%...

Lilly's Ixekizumab Superior to Etanercept and Placebo in Phase 3 Psoriasis Studies

INDIANAPOLIS, Aug. 21, 2014 /PRNewswire/ --

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer

ENSPIRIT Trial to Continue as Planned Following Completion of the First of Two Interim Futility Analyses

BOTHELL, Wash. and

BIOGEN IDEC NAMES ADRIANA KARABOUTIS EVP, TECHNOLOGY AND BUSINESS SOLUTIONS

BIOGEN IDEC NAMES ADRIANA KARABOUTIS EVP, TECHNOLOGY AND BUSINESS SOLUTIONS Thursday, August 21, 2014 7:00 am EDT Dell CIO to Lead Biogen Idec's IT and Technology Innovation Initiatives CAMBRIDGE,...

Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer

Galena Biopharma Appoints Mark W. Schwartz, Ph.D., as President and Chief Executive Officer PORTLAND, Ore., Aug. 21, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE), a biopharmaceutical...

Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis

New CE mark in the European Union extends application to routine pathology including primary diagnosis with human tissue specimens

TUCSON

GSK receives FDA approval for Arnuity™ Ellipta® (fluticasone furoate) in the US for the treatment of asthma

GlaxoSmithKline plc today announced that the FDA has approved Arnuity™ Ellipta® (fluticasone furoate inhalation powder), a once-daily inhaled corticosteroid (ICS) medicine for maintenance...

FDA Approves Genzyme's Cerdelga™ (eliglustat) Capsules

Only First-Line Oral Therapy Approved for the Treatment of Adults with Gaucher Disease Type 1 CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced...

Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024

Depomed Prevails in Gralise® ANDA Litigation Blocking Generic Entry Until 2024 NEWARK, Calif., Aug. 19, 2014 /PRNewswire/ -- Depomed, Inc. DEPO, -0.04% today announced Judge Joel A. Pisano of the...

Allergan Names Jim Hindman Chief Financial Officer

Jeff Edwards to Step Down Due to Family Commitments IRVINE, Calif.--(BUSINESS WIRE)-- Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today announced that Jim Hindman...